Press Releases
-
TIF’s Statement on Accessibility of Gene Therapy for Thalassaemia
The Thalassaemia International Federation (TIF) expresses its disappointment about the outcome of the reimbursement negotiation process concerning gene therapy (Zynteglo™) for transfusion-dependent thalassaemia patients, announced last week. The Federation’s distress…
Read More » -
-
TIF leads the way in creating a Community Advisory Board (CAB) in Europe for thalassaemia and sickle cell disease
ANNOUNCEMENT: Dear friends and esteemed collaborators, The Thalassaemia International Federation (TIF) since its establishment in 1986 has been a pioneer in providing the patients’ perspective in all health-related…
Read More » -
-
Sir David Weatherall, an ‘iconic’ scientist who carried out groundbreaking work in thalassaemia, dies
The international scientific and research community is mourning the loss of Sir David Weatherall, the highly-regarded British clinical scientist and haematologist whose studies focused on haemoglobin disorders and thalassaemia. His…
Read More » -
Juggling Between The Cost And Value of New Therapies: Does Science Still Serve Patient Needs?
In the aftermath of the withdrawal of Zynteglo, the first gene therapy for patients with β-thalassaemia, from Europe, TIF´s Executive Director, Dr Androulla Eleftheriou, reflects on the viability of the…
Read More » -
International Thalassaemia Day 2021: Official Global Press Release
On International Thalassaemia Day, TIF shines a light on the striking health inequalities that affect the global thalassaemia community, further accentuated by the ongoing coronavirus pandemic. NICOSIA, May 5, 2021/Thalassaemia International…
Read More »